• 1. Excimer emission and magnetoluminescence of radical-based zinc(ii) complexes doped in host crystals?
  Shojiro Kimura,Tetsuro Kusamoto Chem. Commun., 2020,56, 11195-11198
• 2. Enabling chloride salts for thermal energy storage: implications of salt purity?
  J. Matthew Kurley,Phillip W. Halstenberg,Abbey McAlister,Stephen Raiman,Richard T. Mayes RSC Adv., 2019,9, 25602-25608
• 3. Fast-pulsing NMR techniques for the detection of weak interactions: successful natural abundance probe of hydrogen bonds in peptides?
  Amandine Altmayer-Henzien,Valérie Declerck,David J. Aitken,Ewen Lescop,Denis Merlet,Jonathan Farjon Org. Biomol. Chem., 2013,11, 7611-7615
• 4. Enabling non-flammable Li-metal batteries via electrolyte functionalization and interface engineering?
  Jing Yu,Yu-Qi Lyu,Jiapeng Liu,Mohammed B. Effat,Junxiong Wu J. Mater. Chem. A, 2019,7, 17995-18002
• 5. Evolution of calcium phosphate precipitation in hanging drop vapor diffusion by in situRaman microspectroscopy
  Gloria Belén Ramírez-Rodríguez,José Manuel Delgado-López,Jaime Gómez-Morales CrystEngComm, 2013,15, 2206-2212

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Phenethylamines

Recent Advances in the Application of 4-(4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)phenethyl)morpholine (CAS: 364794-81-0) in Chemical Biology and Pharmaceutical Research

The compound 4-(4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)phenethyl)morpholine (CAS: 364794-81-0) has recently garnered significant attention in the field of chemical biology and pharmaceutical research due to its unique structural properties and potential applications in drug discovery and development. This boronic acid derivative, featuring a morpholine moiety, has been explored for its utility in Suzuki-Miyaura cross-coupling reactions, targeted drug delivery, and as a key intermediate in the synthesis of bioactive molecules. Recent studies have highlighted its role in the development of novel therapeutics, particularly in oncology and neurodegenerative diseases.

One of the most notable advancements involves the use of this compound in the synthesis of boron-containing small molecules for proteolysis-targeting chimeras (PROTACs). PROTACs are a promising class of therapeutics that selectively degrade disease-causing proteins by recruiting the ubiquitin-proteasome system. The boronic acid functionality of 364794-81-0 enables efficient conjugation to target proteins, enhancing the specificity and efficacy of PROTACs. Recent preclinical studies have demonstrated its potential in degrading oncogenic proteins such as EGFR and BRAF, offering new avenues for cancer treatment.

In addition to its applications in PROTACs, 364794-81-0 has been investigated as a versatile building block in medicinal chemistry. Its stability under physiological conditions and compatibility with various reaction conditions make it an attractive candidate for the development of boron-based drugs. For instance, researchers have utilized this compound to synthesize boronate esters, which exhibit enhanced bioavailability and target engagement compared to their non-boron counterparts. These findings underscore the compound's potential in addressing challenges related to drug resistance and poor pharmacokinetics.

Another emerging area of research involves the use of 364794-81-0 in positron emission tomography (PET) imaging. The boron atom in the compound can be replaced with fluorine-18, a radioactive isotope, enabling the development of novel PET tracers for imaging diseases such as Alzheimer's and Parkinson's. Recent studies have reported the successful synthesis of fluorine-18 labeled analogs, demonstrating high binding affinity and selectivity for amyloid plaques and tau tangles, which are hallmark pathological features of neurodegenerative diseases.

Despite these promising developments, challenges remain in the clinical translation of 364794-81-0-based therapeutics. Issues such as off-target effects, metabolic instability, and limited tissue penetration need to be addressed through further optimization and structural modification. Ongoing research is focused on improving the pharmacokinetic and pharmacodynamic properties of this compound, with the aim of advancing it into clinical trials. Collaborative efforts between academia and industry are expected to accelerate the translation of these findings into viable therapeutic options.

In conclusion, 4-(4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)phenethyl)morpholine (CAS: 364794-81-0) represents a versatile and promising scaffold in chemical biology and pharmaceutical research. Its applications in PROTACs, medicinal chemistry, and PET imaging highlight its potential to address unmet medical needs. Continued research and development efforts are essential to fully realize the therapeutic potential of this compound and overcome existing challenges.

• 364794-82-1(4-{2-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenylethyl}morpholine)
• 944591-57-5(4-((Morpholino)methyl)phenylboronic Acid Pinacol Ester Hydrochloride)
• 364794-79-6(4-[[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]methyl]morpholine)
• 876316-33-5(2-(4-Morpholinomethyl)phenylboronic Acid Pinacol Ester)
• 1315281-49-2(2-4-(4,4,5,5-Tetramethyl-1,3,2dioxaborolan-2-Yl)-benzyl-1,2,3,4-tetrahydro-isoquinoline)
• 1073371-76-2(3-(Morpholino)methylphenylboronic Acid Pinacol Ester Hydrochloride)
• 364794-80-9(4-[[3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]methyl]morpholine)
• 1092563-23-9(1-morpholino-2-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]ethanone)
• 1150271-51-4(2-(2-Methoxyethyl)aminomethylphenylboronic Acid Pinacol Ester)
• 1150271-72-9(3-(3-Morpholinopropyl)phenylboronic Acid Pinacol Ester Hydrochloride)